Purdue Pharma L.P. Patent applications |
Patent application number | Title | Published |
20160024022 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A | 01-28-2016 |
20160022787 | Peptide Immunogens - The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. | 01-28-2016 |
20150306093 | TRANSDERMAL DELIVERY SYSTEM - The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-containing self-adhesive layer structure contains said buprenorphine in an amount of less than 0.8 mg/cm2 buprenorphine base or an equimolar amount of a pharmaceutically acceptable salt thereof. | 10-29-2015 |
20150265536 | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(EPSILON-CAPROLACTONE) AND POLYETHYLENE OXIDE - The present invention relates to a solid extended release pharmaceutical dosage form, comprising a mixture in the form of an extended release matrix formulation, the mixture comprising at least: (1) at least one poly(ε-caprolactone), and (2) at least one polyethylene oxide, and (3) at least one active agent. | 09-24-2015 |
20150191517 | NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF - The present invention relates to C-terminal modified Protoxin II peptides that selectively inhibit the Nav1.7 sodium channel; the present invention also relates to pharmaceutical compositions useful for prophylactic or therapeutic treatment of a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels; the present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels. | 07-09-2015 |
20150190393 | USE OF OXYCODONE FOR TREATING VISCERAL PAIN - It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of the other opioids like morphine. | 07-09-2015 |
20150182474 | DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORM - The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. | 07-02-2015 |
20140364448 | QUARTERNIZED BUPRENORPHINE ANALOGS - The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R | 12-11-2014 |
20140323512 | Acrylic Polymer Formulations - Disclosed herein are oral solid dosage forms comprising purified neutral acrylic polymer, methods of treating a disease or condition using the same, and methods of preparing the same. | 10-30-2014 |
20140315783 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides pyrimidine diol amides of Formula (I), and the pharmaceutically acceptable solvates and prodrugs thereof, wherein A | 10-23-2014 |
20140309228 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides substituted pyridine and pyrimidine compounds of Formula (I): A1-X-A2-Z-R1 (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein A, X, A, Z, and R are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain. | 10-16-2014 |
20140288092 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS - The invention relates to aryl substituted compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein Het, G, A, R, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain. | 09-25-2014 |
20140275117 | BUPRENORPHINE ANALOGS - The present invention is directed to Buprenorphine Analog compounds of Formula I, II, III, IV or V and including various stereoisomers (such as Formula IA shown below), wherein R | 09-18-2014 |
20140271896 | TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS - Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material. | 09-18-2014 |
20140256764 | TAMPER RESISTANT DOSAGE FORM COMPRISING AN ADSORBENT AND AN ADVERSE AGENT - Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms. | 09-11-2014 |
20140250224 | ADVERSE EVENT DATA CAPTURE AND ALERT SYSTEMS AND METHODS - Electronic capture of adverse event information includes selective input of adverse event information into a machine in response to prompt provided to the user based on a site visit. Such adverse event information is forwardable to a location over a communication link. The machine produces one or more alerts, if adverse event information has been input, after a prescribed period of time has transpired unless the machine is informed that the same information has already been forwarded to the location. In a preferred embodiment, the customer is a clinician. Optionally, received adverse event information can be parsed to audit whether any of the information, in fact, concerns an adverse event. Systems and software concerning related technological improvements are disclosed. | 09-04-2014 |
20140249185 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 09-04-2014 |
20140249128 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides substituted triazine carboxamides of Formula I: | 09-04-2014 |
20140221419 | BENZOMORPHAN ANALOGS AND THE USE THEREOF - The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R | 08-07-2014 |
20140221416 | Tamper Resistant Pharmaceutical Formulations - Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse. | 08-07-2014 |
20140221413 | PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN - A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain. | 08-07-2014 |
20140213606 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 07-31-2014 |
20140199394 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 07-17-2014 |
20140187573 | Substituted Morphinans and the Use Thereof - The application is directed to compounds of Formula I: | 07-03-2014 |
20140187571 | 7,8-Cyclicmorphinan Analogs - The application is directed to compounds of Formula I-A | 07-03-2014 |
20140187544 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): | 07-03-2014 |
20140187535 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I): | 07-03-2014 |
20140179724 | Spirocyclic Morphinans and Their Use - The application is directed to compounds of Formula I′-A | 06-26-2014 |
20140171643 | METHODS FOR MAKING 3-O-PROTECTED MORPHINONES AND 3-O-PROTECTED MORPHINONE DIENOL CARBOXYLATES - Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R | 06-19-2014 |
20140171461 | Nitrogen Containing Morphinan Derivatives and the Use Thereof - The application is directed to compounds of Formula I-A | 06-19-2014 |
20140163058 | BUPRENORPHINE ANALOGS - The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II, Formula III, Formula IV, and Formula V, wherein R | 06-12-2014 |
20140155426 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 06-05-2014 |
20140149134 | Pharmaceutical Representative Expense Report Management Software, Systems, And Methodologies - Electronic assigning of expense data related to sales calls to customers such as health care professionals (HCPs) aids in complying with local, state, federal, or other regulatory reporting requirements and guidelines. The method includes providing expense report data and presenting a line-item entry of the report on a display. Through a user interface, one or more customers included within a database are selected. An expense amount associated with the line-item entry is automatically allocated into dollar amounts among the selected customer(s) and entries in the database are updated for each selected customer to now include the allocated dollar amounts. | 05-29-2014 |
20140142112 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 05-22-2014 |
20140135351 | Benzomorphan Analogs and the Use Thereof - The present invention is directed to Benzomorphan Analog compounds of the Formula I″, Formula IA″, Formula IB″, Formula IC″, or Formula ID″ as shown below; and related Formula I′, Formula IA′, Formula IB′, Formula IC′, or Formula ID′; Formula I, Formula IA, Formula IB, Formula IC, or Formula ID; wherein R | 05-15-2014 |
20140128346 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): | 05-08-2014 |
20140112981 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 04-24-2014 |
20140073663 | METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 03-13-2014 |
20140057931 | BUPRENORPHINE ANALOGS - The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R | 02-27-2014 |
20140056979 | Controlled Release Pharmaceutical Dosage Forms - The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release. | 02-27-2014 |
20140050749 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues - The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. The exemplary polypeptides are derived from the survivin, hTERT, CYP1B1 and MART-1 antigens. | 02-20-2014 |
20140045877 | PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE - The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner. | 02-13-2014 |
20140045875 | Fused and Spirocycle Compounds and the Use Thereof - The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R | 02-13-2014 |
20140045830 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): | 02-13-2014 |
20140011832 | Encased Tamper Resistant Controlled Release Dosage Forms - In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C. | 01-09-2014 |
20140005212 | Substituted Pyridines as Sodium Channel Blockers | 01-02-2014 |
20130345211 | Pyridine Compounds as Sodium Channel Blockers - The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof wherein A | 12-26-2013 |
20130338170 | TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA | 12-19-2013 |
20130309303 | Opiod Agonist Formulations with Releasable And Sequestered Antagonist - Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof. | 11-21-2013 |
20130303526 | Pyridine Compounds and the Uses Thereof - The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R | 11-14-2013 |
20130296281 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels - The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R | 11-07-2013 |
20130296247 | Analogs of Sodium Channel Peptide Toxin - The present invention relates to a peptide and analogs thereof that selectively inhibit the Na | 11-07-2013 |
20130289044 | Quinazoline Compounds as Sodium Channel Blockers - The invention relates to aryl substituted quinazolines of Formula I, and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, A, and R | 10-31-2013 |
20130261143 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 10-03-2013 |
20130259941 | CONTROLLED RELEASE DOSAGE FORMS - Dosage forms having a core having a surface having means for controlling release(s) on an active agent(s); methods of manufacturing, tools used in manufacturing; and uses of the dosage forms are described. | 10-03-2013 |
20130240384 | Vacuum Avoiding Packaging Systems and Methods Thereof - Disclosed in certain embodiments is a packaging system comprising a container ( | 09-19-2013 |
20130217716 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 08-22-2013 |
20130197020 | Method of Providing Sustained Analgesia With Buprenorphine - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 08-01-2013 |
20130171259 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 07-04-2013 |
20130158061 | CONTROLLED RELEASE HYDROCODONE - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 06-20-2013 |
20130150377 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof - The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R | 06-13-2013 |
20130012541 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 01-10-2013 |
20130012533 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises wet granulating at least one hydrophilic or hydrophobic polymer, preferably a hydroxyalkyl cellulose or an alkyl cellulose, with oxycodone or a salt thereof to form a controlled-release matrix. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration. | 01-10-2013 |
20130011543 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for preparing a solid oral dosage form comprising up to about 160 mg of oxycodone or a salt thereof to control pain in substantially all patients is disclosed. The method comprises forming spheroids comprising a spheronising agent and oxycodone or a salt thereof, and coating the spheroids with a controlled-release film coat. Repeated “q12h” (i.e., every 12 hour) administration of the dosage form through steady-state conditions results in a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after administration. | 01-10-2013 |
20120322830 | Cyclourea Compounds as Calcium Channel Blockers - The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R | 12-20-2012 |
20120309778 | Fused and Spirocycle Compounds and the Use Thereof - The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R | 12-06-2012 |
20120263788 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 10-18-2012 |
20120225902 | METHODS FOR MAKING 3-O-PROTECTED MORPHINONES AND 3-O-PROTECTED MORPHINONE DIENOL CARBOXYLATES - Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R | 09-06-2012 |
20120215739 | DATA CACHE TECHNIQUES IN SUPPORT OF SYNCHRONIZATION OF DATABASES IN A DISTRIBUTED ENVIRONMENT - A method for synchronizing a database server to a current status of a client database using data cache techniques is provided. Upon initiating synchronization, the database server receives an identification of a client connection, and creates a server-cache-table having a structure that is compatible with the client database. Database records from a corresponding client-cache-table are received through the client connection and inserted into the server-cache-table. The server-cache-table is merged into the database server. Similar cache-tables can be utilized to synchronize data from the database server to the client. Optionally, a parent-cache-table can be created on the server and populated with records associated with the identified client. Queries and other database operations during synchronization can be performed over the parent-cache-table to further optimize performance. | 08-23-2012 |
20120177570 | TRPV1 ANTAGONISTS INCLUDING AMIDE SUBSTITUENT AND USES THEREOF - The invention relates to compounds of formula IA″ | 07-12-2012 |
20120165336 | Color Change Time Indicator for Packaging System - Disclosed in certain embodiments is a pharmaceutical packaging system comprising: a receptacle comprising an openable seal for accessing the interior of the receptacle; a pharmaceutical dosage form contained in the receptacle; and an activatable color-changing material, wherein upon activation, the material exhibits a visually discernible color change upon the lapsing of a predetermined time period. | 06-28-2012 |
20120164220 | Encased Tamper Resistant Controlled Release Dosage Forms - In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C. | 06-28-2012 |
20120149892 | Nucleic Acid Molecules Encoding Antibodies That Bind Cell-Associated CA 125/O772P - The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. | 06-14-2012 |
20120123335 | TRANSDERMAL PATCH WITH ON-BOARD ENERGY STORAGE DEVICE - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-17-2012 |
20120116314 | TRANSDERMAL PATCH WITH PULL-TAB ACTUATED ENERGY STORAGE DEVICES - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-10-2012 |
20120116308 | TRANSDERMAL PATCH WITH PLURAL ON-BOARD ENERGY STORAGE DEVICES - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-10-2012 |
20120108622 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-03-2012 |
20120108621 | PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE - The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner. | 05-03-2012 |
20120108575 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF - The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound. | 05-03-2012 |
20120095049 | NOCICEPTIN ANALOGS - A compound of the formula (I), (II), (III) or (IV) | 04-19-2012 |
20120022259 | METHODS FOR MAKING 3-O-PROTECTED MORPHINONES AND 3-O-PROTECTED MORPHINONE DIENOL CARBOXYLATES - Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R | 01-26-2012 |
20120015954 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-19-2012 |
20120004941 | CYCLE PLANNING TOOL WITH EVENT CONFLICT RESOLUTION FOR TERRITORY MANAGEMENT - Electronically creating a schedule plan of events which replicates one or more previously scheduled events. A source date range is acquired into a memory of a machine A set of previously scheduled events within the source date range is identified. A target date range is received through a user interface. At least a portion of the previously scheduled events is assigned to a date within the received target date range to create the schedule plan. The schedule plan is posted to a calendar. Another method creates a schedule plan on the basis of one or more search criteria used for identifying any match from a database. At least a portion of any matches are assigned a time slot within a target date range of a calendar program. | 01-05-2012 |
20120004217 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-05-2012 |
20110288100 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 11-24-2011 |
20110281885 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 11-17-2011 |
20110281876 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula: | 11-17-2011 |
20110262532 | Controlled Release Hydrocodone Formulations - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 10-27-2011 |
20110217243 | PHARMACEUTICAL IDENTIFICATION - Disclosed are methods for marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical. | 09-08-2011 |
20110207762 | OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 08-25-2011 |
20110152324 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 06-23-2011 |
20110136846 | Buprenorphine Analogs - The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II or Formula III shown below, wherein R | 06-09-2011 |
20110104214 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 05-05-2011 |
20110098281 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 04-28-2011 |
20110082152 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 04-07-2011 |
20110071192 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 03-24-2011 |
20110038927 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 02-17-2011 |
20110009418 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula: | 01-13-2011 |
20110002975 | PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN - A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain. | 01-06-2011 |
20100331369 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 12-30-2010 |
20100324080 | Benzomorphan Compounds - The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R | 12-23-2010 |
20100317670 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 12-16-2010 |
20100261713 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 10-14-2010 |
20100240675 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - Compounds of formulae: | 09-23-2010 |
20100234426 | Phenylpropionamide Compounds and the Use Thereof - The invention relates to phenylpropionamide compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A, B, R | 09-16-2010 |
20100216726 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof - The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound. | 08-26-2010 |
20100210686 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In one embodiment, the Piperidine Compound has the formula: | 08-19-2010 |
20100152449 | 8a,14-DIHYDROXY-7,8-DIHYDROCODEINONE - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 06-17-2010 |
20100092570 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 04-15-2010 |
20100069437 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - 4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound are disclosed. | 03-18-2010 |
20100063030 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 03-11-2010 |
20100034876 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 02-11-2010 |
20100022595 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels - The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 01-28-2010 |
20100022439 | Nanostructures with High Load of Active Agents - The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end of the time period. | 01-28-2010 |
20100004254 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-07-2010 |
20090291947 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS - The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof. | 11-26-2009 |
20090253727 | NOCICEPTIN ANALOGS - A compound of the having the general formula (I) or general formula (II): | 10-08-2009 |
20090202629 | Controlled release hydrocodone formulations - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 08-13-2009 |
20090176838 | Cyclourea Compounds as Calcium Channel Blockers - The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R | 07-09-2009 |
20090083334 | SYSTEM AND METHODS FOR MANAGEMENT OF RISK DATA AND ANALYTICS - Managing and analyzing occurrences of certain types of adverse events associated with a distribution of a prescription drug into the commercial marketplace, such as a drug having an associated abuse liability potential. Data concerning an occurrence of an adverse event associated with such distribution is received and selectively logged as an event if the data satisfies one or more predetermined criteria which can be used to filter the received data. If the received data are logged as an event, a score is computed and assigned to the event. If the score meets or exceeds a pre-established threshold, a field researcher is assigned to investigate the logged event. Further data from the field researcher are stored in association with the logged event. Automated review of further data from field researchers can be performed to update the status of a logged event to closed. | 03-26-2009 |
20090081287 | Pharmaceutical Composition Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 03-26-2009 |
20090081200 | Tissue Factor Antibodies and Uses Thereof - The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention. | 03-26-2009 |
20090042902 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 02-12-2009 |
20090008401 | Dispenser with Corner Latches - A dispenser having a storage compartment may hold a blister package or other object. The blister package may be slid in and out of the dispenser through an opening. Corner latches pivotally attached to the dispenser on either side of the opening move between a first position and a second position. In the first position, a portion of the corner latches extend into the opening thereby preventing the object from being removed from the dispenser. The corner latches are moved to the second position such that the corner latches no longer block the opening to the dispenser so that the blister package may be removed. | 01-08-2009 |
20090008286 | Dispenser with a Spout - A dispenser with a spout holds a plurality of objects, such as pharmaceutical dosage forms. The dispenser has a housing defining an interior space that holds the pharmaceutical products and an opening leading to the interior space. A movable spout is disposed in the opening and is able to pivot between a closed position wherein the opening is occluded, or sufficiently occluded, by the spout thereby preventing objects disposed within the interior space from exiting the housing through the opening and an open position wherein the opening is not occluded, or sufficiently unoccluded, by the spout thereby permitting objects disposed within the interior space to exit the housing through the opening. The dispenser also has an opener with a push button for moving the spout from the closed position to the open position about the pivot axis when pressure is applied to the opener wherein the opener engages one end of the spout below the pivot axis to push another end of the spout outward from the housing. | 01-08-2009 |
20080318932 | Sodium Channel Blocker Compositions and the Use Thereof - Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion. | 12-25-2008 |
20080281858 | ITINERARY SEARCH TOOL FOR TERRITORY MANAGEMENT - Electronically creating an itinerary schedule in a calendar program. A geographic indicator and a calendar date are acquired and coordinated with each other to define an itinerary entry. The itinerary entry is included into a calendar program maintained by the machine. The step of acquiring the geographic indicator further comprises the step of updating a counter upon each selection of a geographic indicator. Another method electronically populates a calendar program with an event using an itinerary entry. Optionally, health care providers from within a geographic indicator are included in the itinerary entry. A geographic indicator and calendar date are obtained from an itinerary entry, and additional search criteria are input. A search of a database is executed to identify candidates matching the geographic indicator and search criteria. Candidate matches are assigned to a time slot, and each time slot is populated into the calendar program on the calendar date. | 11-13-2008 |
20080262284 | DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORM - The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. | 10-23-2008 |